Answers are grounded in this paper and cite their sources.
MGMT promoter hypermethylation appears to be a useful marker for predicting survival in patients with B-DLCL treated with multidrug regimens including cyclophosphamide.
No takes yet. Share an insight, caveat, or question.
Manel Esteller (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: